+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Helsinki Heart Study. New perspectives in the prevention of coronary heart disease



Helsinki Heart Study. New perspectives in the prevention of coronary heart disease



Drugs 36(Suppl. 3): 32-36



The Helsinki Heart Study tested the effect of modifying plasma low density lipoprotein (LDL)- and high density lipoprotein (HDL)-cholesterol on the primary prevention of coronary heart disease in middle-aged men with non-HDL-cholesterol greater than or equal to 5.2 mmol/L (200 mg/dl). One group (2046 men) received 600mg of gemfibrozil twice daily, and the other (2035 men) received placebo. Averaged over the 5-year trial period, gemfibrozil induced mean decreases of 11% in LDL-cholesterol and 35% in triglycerides and a mean increase of 11% in HDL-cholesterol compared with placebo. These changes were accompanied by a 34% reduction (number of end-points; 56 vs 84) in the incidence of coronary heart disease. The reduction was largest in subjects with type IIB hyperlipoproteinaemia and smallest in subjects with type IIA hyperlipoproteinaemia. The changes in serum HDL- and LDL-cholesterol during the trial were associated (p less than 0.02 and p less than 0.05, respectively) with the risk of coronary heart disease in the gemfibrozil group, but not in the placebo group.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040260228

Download citation: RISBibTeXText

PMID: 3076118


Related references

Helsinki heart study primary prevention of coronary heart disease by modulating lipids with gemfibrozil. European Heart Journal 9(ABSTR Suppl. 1): 269, 1988

Pathogenesis, prevention and treatment of coronary heart disease. Proceedings of the Helsinki Heart Symposium. Hanasaari, Finland, June 1-2, 1984. Acta Medica Scandinavica. Supplementum 701: 1-154, 1985

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine 317(20): 1237-1245, 1987

The prognostic value of triglycerides in coronary heart disease findings from the helsinki heart study. Gotto, A M Jr And R Paoletti (Ed ) Atherosclerosis Reviews, Vol 22 Triglycerides: The Role in Diabetes And Atherosclerosis; International Symposium, Vienna, Austria, May 23-26, 1990 Xiii+232p Raven Press: New York, New York, Usa Illus 71-74, 1991

The Helsinki Heart Study: Coronary heart disease incidence during an extended follow-up. Journal of Internal Medicine 235(1): 41-49, 1994

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15(7): 820-825, 1992

Low hdl cholesterol and coronary heart disease risk helsinki heart study experience finland. Miller, N E And A R Tall (Ed ) International Congress Series, No 1001 High Density Lipoproteins And Atherosclerosis, Iii; 3rd International Symposium on Plasma High Density Lipoproteins And Atherosclerosis, San Antonio, Texas, Usa, March 4-6, Ix+270p Elsevier Science Publishers B V : Amsterdam, Netherlands; New York, New York, Usa Illus 253-257, 1992

The sense of coherence, occupation and the risk of coronary heart disease in the Helsinki Heart Study. Social Science and Medicine 49(1): 109-120, 1999

HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study. Drugs 40(Suppl. 1): 7, 1990

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260(5): 641-651, 1988

Shift work, occupation and coronary heart disease over 6 years of follow-up in the Helsinki Heart Study. Scandinavian Journal of Work, Environment & Health 23(4): 257-265, 1997

Lipoproteins and coronary heart disease in the Helsinki Heart Study. European Heart Journal 11 Suppl H: 26-31, 1990

Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. American Journal of Cardiology 63(16): 42h-47h, 1989

Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Annals of Internal Medicine 116(4): 273-278, 1992

Antihypertensive therapy in dyslipidemic subjects Effect on coronary heart disease incidence in the Helsinki Heart Study. European Heart Journal 14(ABSTR Suppl. ): 19, 1993